Skip to main content
Fig. 3 | Experimental Hematology & Oncology

Fig. 3

From: A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy

Fig. 3

In vivo validation of CD22 CAR-T and CD22/CD19 sequential CAR-T cells in wild-type Namalwa inoculated mice model. a Schematic of in vivo evaluation of CAR-T. NOD/SCID mice were challenged with 2 × 106 wild type Namalwa cells on day 0, Mice in the sequential treatment group received 6 × 106 CD22 CAR-T(infection efficiency 50%–60%) cells on day 4 and 6 × 106 CD19 CAR-T (infection efficiency 50%–60%) cells on day 5. Mice in the CD19 CAR-T group received 6 × 106 CD19 CAR-T cells on day 4 and and day 5, respectively. Mice in the CD22 CAR-T group received 6 × 106 CD22 CAR-Tcells on day 4 and day 5, respectively. b. IVIS imaging of disease burden monitored by BLI at the indicated time points. c. Average radiance quantification (p/sec/cm2/sr) for Namalwa at the indicated time points. d T cell persistence in peripheral blood on day 20. (n = 5 per column) e Average body weight of two groups after CAR-T cell treatment. f Kaplan–Meier survival curves of VEC-T and CAR-T treatment groups. The P-values were determined by log-rank test. P < 0.001 when group Vector-T compared with CAR-T. N = 5–6 for VEC-T or CAR-T group

Back to article page